Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinic...

by Piyush Patel, Hanmant Barkate
Published 2016-01-01

Existing problems and new possibilities in the treatment of dyslipidemia Joint Conclusion Based on the Results of the Expert Council

by M. V. Ezhov, V. V. Kukharchuk, I. V. Sergienko, N. M. Akhmedzhanov, M. I. Voevoda, V. S. Gurevich, V. V. Kashtalap, V. O. Konstantinov, V. V. Skibitsky, I. I. Shaposhnik
Published 2021-03-01

Comparison of efficacy and safety of fixed dose combination of rosuvastatin and choline fenofibrate to fixed dose combination of rosuvastatin and fenofibrate in patients of mixed d...

by Hanmant Barkate, Piyush Patel, Dimple Shah, Falgun Vyas
Published 2018-01-01

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

by Michel Farnier
Published 2008-10-01

Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies

by Heidi T. May, Joseph B. Muhlestein, Yuhui Ma, J. Antonio G. López, Blai Coll, John Nelson
Published 2019-03-01

Cardiometabolic Risk Factors in Rosuvastatin-Treated Men with Mixed Dyslipidemia and Early-Onset Androgenic Alopecia

by Robert Krysiak, Marcin Basiak, Bogusław Okopień
Published 2021-05-01